Skip to main content
SpringerLink
Log in

Use of recombinant human erythropoietin in the treatment of myelodysplastic syndromes

  • Chapter
Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology

  • 150 Accesses

Abstract

Myelodysplastic syndromes (MDSs) are clonal proliferations of multipotent bone marrow stem cells which retain their capacity to differentiate but do so in an inefficient manner, so that mature blood cells are variably reduced (Gallagher et al. 1997; Aul et al. 1998; Vallespí et al. 1998). With time there is a progressive impairment in the capacity of stem cells to differentiate and an increasingly high risk of evolution to overt acute myeloid leukemia. Although the clinical course of these disorders is highly variable from patient to patient, the International Prognostic Scoring System (Greenberg et al. 1997) provides an improved method for evaluating prognosis in individual MDS patients (Sanz et al. 1998).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aul C, Bowen DT, Yoshida Y (1998) Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 83: 71–86

    PubMed  CAS  Google Scholar 

  2. Bessho M, Jinnai I, Hirashima K et al (1994) Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia. Stem Cells 12: 604–615

    Article  PubMed  CAS  Google Scholar 

  3. Cazzola M, Anderson JE, Ganser A, Hellström-Lindberg E (1998) A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica 83: 910–935

    PubMed  CAS  Google Scholar 

  4. Cazzola M, Guarnone R, Cerani P, Centenara E, Rovati A (1998) Red cell precursor mass as an independent determinant of serum erythropoietin level. Blood 91: 2139–2145

    PubMed  CAS  Google Scholar 

  5. Cazzola M, Mercuriali F, Brugnara C (1997) Clinical use of recombinant human erythropoietin outside the setting of uremia. Blood 89: 4248–4267

    PubMed  CAS  Google Scholar 

  6. Cazzola M, Ponchio L (1992) Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders [letter]. Blood 80: 841–843

    Google Scholar 

  7. Gallagher A, Darley RL, Padua R (1997) The molecular basis of myelodysplastic syndromes. Haematologica 82: 191–204

    PubMed  CAS  Google Scholar 

  8. Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079–2088

    PubMed  CAS  Google Scholar 

  9. Hellström-Lindberg E (1995) Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 89: 67–71

    PubMed  Google Scholar 

  10. Hellström-Lindberg E, Ahlgren T, Beguin Y et al (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92: 68–75

    PubMed  Google Scholar 

  11. Hellström-Lindberg E, Birgegârd G, Carlsson M et al (1993) A combination of granulocyte-colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma 11: 221–228

    Article  PubMed  Google Scholar 

  12. Hellström-Lindberg E, Negrin R, Stein R et al (1997) Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 99: 344–351

    Article  PubMed  Google Scholar 

  13. Imamura M, Kobayashi M, Kobayashi S et al (1994) Failure of combination therapy with granulocyte colony-stimulating factor and erythropoietin in myelodysplastic syndromes. Ann Hematol 68: 163–166

    Article  PubMed  CAS  Google Scholar 

  14. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes (1998) A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 103: 1070–1074

    Article  Google Scholar 

  15. Mantovani L, Lentini G, Hentschel B et al (2000) Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol 109: 367–375

    Article  PubMed  CAS  Google Scholar 

  16. Musto P, Falcone A, Carotenuto M et al (1994) Granulocyte colony-stimulating factor and erythropoietin for the anemia of myelodysplastic syndromes: A real improvement with respect to erythropoietin alone? Blood 84: 1687–1688

    PubMed  CAS  Google Scholar 

  17. Musto P, Sanpaolo G, D’Arena G et al (2001) Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone. Haematologica 86: 44–51

    PubMed  CAS  Google Scholar 

  18. Negrin RS, Stein R, Doherty K et al (1993) Treatment of the anemia of myelodysplastic syndromes using human granulocyte-CSF in combination with erythropoietin. Blood 82: 737–743

    PubMed  CAS  Google Scholar 

  19. Negrin RS, Stein R, Doherty K et al (1996) Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 87: 4076–4081

    PubMed  CAS  Google Scholar 

  20. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L (1995) The use of rHuEpo in the treatment of anaemia related to myelodysplasia ( MDS ). Br J Haematol 89: 831–837

    Google Scholar 

  21. Sanz GF, Sanz MA, Grenberg PL (1998) Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 83: 358–368

    PubMed  CAS  Google Scholar 

  22. Stenke L, Wallvik J, Celsing F, Hast R (1993) Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Leukemia 7: 1324–1327

    PubMed  CAS  Google Scholar 

  23. Vallespí T, Imbert M, Mecucci C, Preudhomme C, Fenaux P (1998) Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica 83: 258–275

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, University of Pavia School of Medicine, IRCCS Policlinico S. Matteo, Pavia, Italy

    Prof. Mario Cazzola

Authors
  1. Prof. Mario Cazzola
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mario Cazzola .

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum, Essen, Universitätsklinikum, Essen, Deutschland

    M. R. Nowrousian

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag/Wien

About this chapter

Cite this chapter

Cazzola, M. (2002). Use of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. In: Nowrousian, M.R. (eds) Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. Springer, Vienna. https://doi.org/10.1007/978-3-7091-7658-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-7658-0_13

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-7660-3

  • Online ISBN: 978-3-7091-7658-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation